Acotec Scientific Holdings Limited (HKG:6669)

Market Cap	4.58B +162.7%
Revenue (ttm)	649.64M +13.3%
Net Income	110.56M +214.6%
EPS	0.36 +210.2%
Shares Out	313.39M
PE Ratio	40.42
Forward PE	35.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,378
Average Volume	327,938
Open	14.77
Previous Close	14.63
Day's Range	14.59 - 14.99
52-Week Range	5.56 - 15.47
Beta	0.21
RSI	60.27
Earnings Date	Mar 25, 2026

About HKG:6669

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 645
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6669

Financial Performance

In 2024, HKG:6669's revenue was 533.99 million, an increase of 12.69% compared to the previous year's 473.85 million. Earnings were 52.28 million, an increase of 260.88%.

Financial numbers in CNY